Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
FS Coelho, M Borges‐Canha… - Diabetes/metabolism …, 2021 - Wiley Online Library
Aims Non‐alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
F dos Santos Coelho, M Borges‐Canha… - … Research and Reviews, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Aims</jats: title>< jats: p> Non‐
alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in …
alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in …
[PDF][PDF] Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
F dos Santos Coelho, M Borges‐Canha, M von Hafe… - researchgate.net
Aims: Non‐alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials
FDS Coelho, M Borges-Canha… - Diabetes …, 2021 - pubmed.ncbi.nlm.nih.gov
Aims Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials.
FS Coelho, M Borges‐Canha… - Diabetes …, 2021 - search.ebscohost.com
Aims: Non‐alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials.
FDS Coelho, M Borges-Canha, M von Hafe… - Diabetes/metabolism …, 2020 - europepmc.org
Aims Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …